Interní Med. 2013; 15(11-12): 334-339

Anticoagulation with new antithrombotic agents - recommendations for daily practice

prof.MUDr.Jan Kvasnička, DrSc., Mgr.Ivana Malíková, doc.MUDr.Tomáš Kvasnička, CSc.
Centrální hematologická laboratoř, ÚLBLD, Všeobecná fakultní nemocnice a 1. LF UK v Praze

The internists can indicate the new oral anticoagulants (rivaroxaban, apixaban and dabigatran) in the treatment of their patients now.

We present an overview of their effects and several advice for possible monitoring in practice.

Keywords: monitoring, rivaroxaban- apixaban, dabigatran

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvasnička J, Malíková I, Kvasnička T. Anticoagulation with new antithrombotic agents - recommendations for daily practice. Interní Med. 2013;15(11-12):334-339.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. The European Medicines Agency. Souhrn údajů o přípravku Xarelto. [online]. Dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.
    2. Čihák R, Haman L, Heinc P. Souhrn Aktualizace doporučených postupů ESC pro léčbu fibrilace síní z roku 2012. Cor et Vasa. 2012; 54: e341-e351. Go to original source...
    3. The European Medicines Agency. Souhrn údajů o přípravku Eliquis. [online]. Dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf.
    4. http://www.haematex.com/?p=200.
    5. The European Medicines Agency. Souhrn údajů o přípravku Pradaxa. [online]. Dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
    6. Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J. 2011; 32: 1968-1976. Go to original source... Go to PubMed...
    7. Siegal DM, Crowther MA. Acute management of bleeding in patiens on novel oral anticoagulants. Eur Heart J 2013; 34: 489-500. Go to original source... Go to PubMed...
    8. Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11: 756-760. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.